Presentation and Management of Cutaneous Manifestations of COVID-19

January 2021 | Volume 20 | Issue 1 | Original Article | 76 | Copyright © January 2021


Published online December 24, 2020

Guilerme Almeida MD,a Suleima Arruda MD,b Elaine Marques MD,a Nichola Michalany MD,c Neil Sadick MDd

aHospital Sirio libanês, São Paulo, Brazil; Olsen de Almeida Dermatology, São Paulo, Brazil
bArruda Dermatology, Sao Paulo, Brazil; Sadick Research Group, New York, NY
cPathologist at Universidade Federal de São Paulo, Sao Paulo, Brazil
dDepratment of Dermatology at Weill Cornell Medical College; Sadick Dermatology; NewYork,NY

DISCLOSURES

The authors declare no conflict of interest; The author have nothing to disclose; The authors received no funding for this work.

REFERENCES

  1. Liu J, Liao X, Qian S, et al. Community transmission of severe acute respiratory syndrome coronavirus 2, Shenzhen, China, 2020. Emerg Infect Dis. 2020;26(6).
  2. Hui DS, E IA, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264-266.
  3. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.
  4. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.
  5. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020.
  6. Yu X, Yang R. COVID-19 transmission through asymptomatic carriers is a challenge to containment. Influenza Other Respir Viruses. 2020;14(4):474- 475.
  7. Zhang J, Wu S, Xu L. Asymptomatic carriers of COVID-19 as a concern for disease prevention and control: more testing, more follow-up. Biosci Trends. 2020.
  8. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020.
  9. Wadman M. Sex hormones signal why virus hits men harder. Science. 2020;368(6495):1038-1039.
  10. Wambier CG, Vano-Galvan S, McCoy J, et al. Androgenetic alopecia present in the majority of hospitalized COVID-19 patients - the "Gabrin sign". J Am Acad Dermatol. 2020.
  11. Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and Cardiovascular disease. Circulation. 2020;141(20):1648-1655.
  12. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.
  13. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177-1179.
  14. Lyu P, Liu X, Zhang R, Shi L, Gao J. The performance of chest CT in evaluating the clinical severity of COVID-19 pneumonia: identifying critical cases based on CT characteristics. Invest Radiol. 2020.
  15. Henry D, Ackerman M, Sancelme E, Finon A, Esteve E. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol. 2020.
  16. Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. J Am Acad Dermatol. 2020;82(5):e177.
  17. Manalo IF, Smith MK, Cheeley J, Jacobs R. A dermatologic manifestation of COVID-19: Transient livedo reticularis. J Am Acad Dermatol. 2020.
  18. Najarian DJ. Morbilliform exanthem associated with COVID-19. JAAD Case Rep. 2020.
  19. Recalcati S. Cutaneous manifestations in COVID-19: A first perspective. J Eur Acad Dermatol Venereol. 2020.
  20. Guarneri C, Venanzi Rullo E, Gallizzi R, et al. Diversity of clinical appearance of cutaneous manifestations in the course of COVID-19. J Eur Acad Dermatol Venereol. 2020.
  21. Recalcati S. Cutaneous manifestations in COVID-19: A first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212-e213.
  22. Rubio-Muniz CA, Puerta-Pena M, Falkenhain-Lopez D, et al. The broad spectrum of dermatological manifestations in COVID-19. Clinical and histopathological features learned from a series of 34 cases. J Eur Acad Dermatol Venereol. 2020.
  23. Tammaro A, Adebanjo GAR, Parisella FR, Pezzuto A, Rello J. Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome. J Eur Acad Dermatol Venereol. 2020.
  24. Yu X, Yang R. COVID-19 transmission through asymptomatic carriers is a challenge to containment. Influenza Other Respir Viruses. 2020.
  25. Bleyzac N, Goutelle S, Bourguignon L, Tod M. Azithromycin for COVID-19: More than just an antimicrobial? Clin Drug Investig. 2020.
  26. Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B. Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19. Clin Pharmacol Ther. 2020.
  27. Gbinigie K, Frie K. Should azithromycin be used to treat COVID-19? A rapid review. BJGP Open. 2020;4(2).
  28. Hughes JH, Sweeney K, Ahadieh S, Ouellet D. Predictions of systemic, intracellular, and lung concentrations of azithromycin with different dosing regimens used in COVID-19 clinical trials. CPT Pharmacometrics Syst Pharmacol. 2020.
  29. Pani A, Lauriola M, Romandini A, Scaglione F. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. Int J Antimicrob Agents. 2020:106053.
  30. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support cortico- steroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473- 475.
  31. Gisondi P, Piaserico S, Conti A, Naldi L. Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice. J Eur Acad Dermatol Venereol. 2020.
  32. Matar S, Oules B, Sohier P, et al. Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature. J Eur Acad Dermatol Venereol. 2020.
  33. Zhao Q, Fang X, Pang Z, Zhang B, Liu H, Zhang F. COVID-19 and cutaneous manifestations: A systematic review. J Eur Acad Dermatol Venereol. 2020.
  34. Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020;9(1):45.
  35. Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S, Nabipour I. COVID-19 cytokine storm: The anger of inflammation. Cytokine. 2020;133:155151.
  36. Phillips TG, Slomiany WP, Allison R. Hair loss: Common causes and treatment. Am Fam Physician. 2017;96(6):371-378.
  37. Veraldi S, Vaira F, Raia DD, Barbareschi M. Telogen effluvium as first clinical presentation of dengue. G Ital Dermatol Venereol. 2017;152(2):184-185.
  38. Di Lernia V. Antipsoriatic treatments during COVID-19 outbreak. Dermatol Ther. 2020:e13345.
  39. TorresT, Puig L. Managing cutaneous immune-mediated diseases during the COVID-19 pandemic. Am J Clin Dermatol. 2020.

AUTHOR CORRESPONDENCE

Neil Sadick MD nssderm@sadickdermatology.com


Close Menu